In general, AMI patients have higher cholesterol levels than CHD patients, and some cholesterol-lowering effect of ABCG5/8 may be sufficient to significantly reduce risk of AMI, an acute CHD type disease, but not sufficient to cause a significant change in overall CHD risk. This evidence concerns the gene ABCG5 and coronary artery disorder.